YOUR MEDTECH GROWTH CAPITAL ADVANTAGE
We leverage deep MedTech expertise and industry relationships to connect founder-led, high-growth companies with aligned growth capital or minority investors, accelerating value creation while supporting founders’ strategies and delivering attractive investor returns.
-
Read More
The Power of Connection: One MedTech CEO to Another
David Brooks of Kinsella Group, speaking from his experience as a former biomaterials CEO, helped us articulate our client’s value in ways others could not.
-
David Brooks of Kinsella Group, speaking from his experience as a former biomaterials CEO, helped us articulate our client’s value in ways others could not.
-
Prerequisites
- Product cleared through FDA 510K or FDA BLA process
- Strong IP
- Established reimbursement code(s)
- KOL and industry consultant support
- TAM in excess of $100 million
- Seeking $5 million or more in growth capital funds
-
- Product cleared through FDA 510K or FDA BLA process
- Strong IP
- Established reimbursement code(s)
- KOL and industry consultant support
- TAM in excess of $100 million
- Seeking $5 million or more in growth capital funds
LET’S CONNECT
Leveraging our resources and industry connections, MedTech organizations seeking to expand can quickly identify and engage growth capital partners or minority investors, streamlining the search and allowing leadership to remain focused on running the business.
Form on the sell page
"*" indicates required fields
Growth Capital Opportunities with Kinsella Group
Examples of innovation, ambition, and the opportunity to positively impact healthcare outcomes
-
New Treatments
Case #1: A company that has developed a new way of treating swelling in the feet and legs using non-painful, neuromuscular stimulation looking to increase its US sales force.
Case #2: A provider of a safer and more cost-effective way to quickly stop bleeding at the femoral entry site following catheter-based heart procedures looking to increase its sales force.
-
New Detection Methods
Case #1: A company that has developed a very early cancer detection system leveraging the smelling ability of C.elegans, a well-studied microscopic worm, that’s looking to enter the US market.
Case #2: A sensor-based insole product developed by a company in the United Kingdom that prevents diabetic foot ulcers (and amputations from diabetic foot ulcers) through earlier detection. Seeking funding to enter the US.
-
Medical Innovation
Case #1: Less traumatic surgery for broken bones by replacing screws that go through the bone with anchors that don’t go through the bone. Company is seeking funding for product development.
Case #2: A developer of quantitative hydration testing system used by major sports teams, manufacturing companies and the military seeking funding to further scale its business and release additional tests for its platform.
The right team with wide reach
Our team of M&A and former MedTech executives have worked in the U.S., Europe, Isreal, Japan, and Taiwan and have extensive networks throughout those markets. Our established methodology and thorough due diligence are designed to deliver strong investor returns and sustainable
enterprise growth for all stakeholders.